MetLife Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

MetLife Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$537K	Buy	120,116 +6,850	+6%	+$31.9K	﹤0.01%	1727
2025 Q4	$623K	Sell	113,266 -13,778	-11%	-$66.9K	﹤0.01%	1685
2025 Q3	$415K	Buy	127,044 +18,966	+18%	+$53.7K	﹤0.01%	1893
2025 Q2	$250K	Buy	108,078 +367	+0.3%	+$797	﹤0.01%	2070
2025 Q1	$150K	Buy	107,711 +44,721	+71%	+$74.8K	﹤0.01%	2344
2024 Q4	$109K	Sell	62,990 -13,047	-17%	-$27.1K	﹤0.01%	2580
2024 Q3	$153K	Buy	76,037 +34,243	+82%	+$75.1K	﹤0.01%	2428
2024 Q2	$93.6K	Buy	+41,794	New	+$122K	﹤0.01%	2638
2022 Q1	–	Sell	-9,509	Closed	-$111K	–	2774
2021 Q4	$111K	Hold	9,509	–	–	﹤0.01%	2374
2021 Q3	$177K	Hold	9,509	–	–	﹤0.01%	2171
2021 Q2	$202K	Buy	+9,509	New	+$219K	﹤0.01%	2170

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's TSHA Position: Q1 2026 in Review

MetLife Investment Management increased its Taysha Gene Therapies (TSHA) stake by 6% in Q1 2026, buying an estimated $31.9K and bringing the position to 120,116 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

MetLife Investment Management first reported a position in TSHA in Q2 2021 and has held it in 11 quarters since. The position peaked at $623K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

MetLife Investment Management held 120,116 shares of Taysha Gene Therapies worth $537K as of Q1 2026.
MetLife Investment Management bought 6,850 Taysha Gene Therapies shares in Q1 2026, an estimated $31.9K.
Taysha Gene Therapies made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1727 holding.
MetLife Investment Management first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 11 quarters since.
MetLife Investment Management's Taysha Gene Therapies position peaked at $623K in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.